Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 7, 2006; 12(33): 5336-5343
Published online Sep 7, 2006. doi: 10.3748/wjg.v12.i33.5336
Published online Sep 7, 2006. doi: 10.3748/wjg.v12.i33.5336
Figure 1 Serum bile acids concentrations (percent values) in gallstone patients (down) and controls (up), before and after placebo and ursodeoxycholic acid treatment.
Each bile acid concentration is expressed as percentages of total serum bile acids. DCA: Deoxycholic acid; CDCA: Chenodeoxycholic acid; CA: Cholic acid; LCA: Lithocholic acid; UDCA: Ursodeoxycholic acid.
Figure 2 Oro-ileal transit time (OITT) in gallstone patients and healthy controls before and after placebo and ursodeoxycholic acid (UDCA) administration.
Figure 3 Gastric half emptying-time (t1/2, min) in gallstone patients and healthy controls before and after placebo and ursodeoxycholic acid (UDCA) administration.
- Citation: Colecchia A, Mazzella G, Sandri L, Azzaroli F, Magliuolo M, Simoni P, Bacchi-Reggiani M, Roda E, Festi D. Ursodeoxycholic acid improves gastrointestinal motility defects in gallstone patients. World J Gastroenterol 2006; 12(33): 5336-5343
- URL: https://www.wjgnet.com/1007-9327/full/v12/i33/5336.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i33.5336